Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 and Semaglutide in Alzheimer's Disease
NCT07651319Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin, semaglutide in Alzheimer's disease (AD), sponsored by Houston Methodist Research Institute. Started Sep 2026; status: recruiting.
02
Drugs
aldesleukinsemaglutide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07651319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07651319.